Market Place
Sourcing Support
ICER calls out drugmakers over `unsupported` price hikes
12 Dec 2024 //
REUTERS
FDA oncology to weigh Exelixis` Cabometyx in neuroendocrine tumors
30 Nov 2024 //
FIERCE PHARMA
Exelixis to Webcast Chats at December Investor Conferences
27 Nov 2024 //
BUSINESSWIRE
Exelixis Provides Update on Cabozantinib for Neuroendocrine Tumors
26 Nov 2024 //
BUSINESSWIRE
Exelixis to Webcast Fireside Chats at November Investor Conferences
07 Nov 2024 //
BUSINESSWIRE
Exelixis Announces Q3 2024 Financial Results and Update
29 Oct 2024 //
BUSINESSWIRE
Exelixis stock rises as Cabometyx withstands patent challenge
16 Oct 2024 //
FIERCE PHARMA
Exelixis Updates On Second Patent Litigation Trial With MSN Labs
15 Oct 2024 //
BUSINESSWIRE
Exelixis To Release Q3 2024 Financial Results On October 29
15 Oct 2024 //
BUSINESSWIRE
Exelixis And Merck Sign Clinical Development Collaboration
14 Oct 2024 //
BUSINESSWIRE
Exelixis presses on with FDA prostate cancer bid as Ipsen scraps EU plan
17 Sep 2024 //
FIERCE PHARMA
Exelixis Presents CABINET Study Results At ESMO 2024
16 Sep 2024 //
BUSINESSWIRE
Exelixis Presents CONTACT-02 Results For Cabozantinib Combo At ESMO
15 Sep 2024 //
BUSINESSWIRE
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
28 Aug 2024 //
BUSINESSWIRE
Invenra Highlights Exelixis` Phase 1 Trial Of XB010 In Advanced Solid Tumors
07 Aug 2024 //
BUSINESSWIRE
FDA Accepts Exelixis` sNDA For Cabozantinib In Advanced NET
06 Aug 2024 //
BUSINESSWIRE
Exelixis Announces Second Quarter 2024 Financial Results and Corporate Update
06 Aug 2024 //
BUSINESSWIRE
Exelixis To Release Q2 2024 Results On August 6
23 Jul 2024 //
BUSINESSWIRE
Ipsen Expands Cabometyx Collaboration For Neuroendocrine Tumors
02 Jul 2024 //
GLOBENEWSWIRE
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
28 May 2024 //
BUSINESSWIRE
Exelixis Settles CABOMETYX Patent Litigation With Cipla
20 May 2024 //
BUSINESSWIRE
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
07 May 2024 //
BUSINESSWIRE
Exelixis Q1 2024 Results and Corporate Update
30 Apr 2024 //
BUSINESSWIRE
Exelixis To Release Q1 2024 Results On 4/30
16 Apr 2024 //
BUSINESSWIRE
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
27 Feb 2024 //
BUSINESSWIRE
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results
06 Feb 2024 //
BUSINESSWIRE
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
01 Feb 2024 //
BUSINESSWIRE
Roche and Exelixis detail rare success for Cabometyx-Tecentriq combo in prostate cancer
26 Jan 2024 //
ENDPTS
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results
23 Jan 2024 //
BUSINESSWIRE
European Patent Office Rules in Favor of Exelixis on Formulation Patent
18 Jan 2024 //
BUSINESSWIRE
Exelixis lays off 175 employees in refocus on emerging pipeline
08 Jan 2024 //
FIERCE BIOTECH
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results
07 Jan 2024 //
BUSINESSWIRE
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
BUSINESSWIRE
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
07 Dec 2023 //
BUSINESSWIRE
Exelixis and Arcus Announce Trial Collaboration to Evaluate Zanzalintinib
04 Dec 2023 //
BUSINESSWIRE
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial
04 Dec 2023 //
BUSINESSWIRE
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference
21 Nov 2023 //
BUSINESSWIRE
Exelixis Announces Results from Expansion Cohort of Phase 1b STELLAR-001 Trial
10 Nov 2023 //
BUSINESSWIRE
Exelixis Announces Third Quarter 2023 Financial Results
01 Nov 2023 //
BUSINESSWIRE
Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength?
27 Oct 2023 //
FINANCE YAHOO
Results from Phase 3 Evaluating Cabozantinib in Neuroendocrine Tumors Presented
22 Oct 2023 //
PRESS RELEASE
Exelixis to Release Third Quarter 2023 Financial Results
18 Oct 2023 //
BUSINESSWIRE
Exelixis licenses small molecule from Insilico for $80M upfront
12 Sep 2023 //
ENDPTS
Exelixis and Insilico Medicine Enter into Agreement for ISM3091
12 Sep 2023 //
BUSINESSWIRE
Exelixis dips into the AI game, LIB cashes in on PCSK9
12 Sep 2023 //
FIERCE BIOTECH
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
31 Aug 2023 //
BUSINESSWIRE
Exelixis ends Cabometyx study after seeing dramatic improvements
25 Aug 2023 //
FIERCE PHARMA
Exelixis Announces Appointment of Amy Peterson as Executive Vice President
23 Aug 2023 //
BUSINESSWIRE
Roche, Exelixis combo triumphs in prostate cancer trial
22 Aug 2023 //
FIERCE PHARMA
Exelixis, Teva reach settlement on Cabometyx patent dispute
25 Jul 2023 //
ENDPTS
Exelixis to Release Q2 2023 Financial Results on Tuesday, August 1, 2023
18 Jul 2023 //
BUSINESSWIRE
Farallon says it`s won board seats from Exelixis after shareholder vote
01 Jun 2023 //
ENDPTS
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
30 May 2023 //
BUSINESSWIRE
Exelixis Announces1Q 2023 FYR and Provides Corporate Update
09 May 2023 //
BUSINESSWIRE
Farallon declares victory ahead of Exelixis proxy battle
09 May 2023 //
FIERCE BIOTECH
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
07 May 2023 //
BUSINESSWIRE
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis
04 May 2023 //
GLOBENEWSWIRE
Exelixis gives more details behind Farallon proxy fight
02 May 2023 //
ENDPTS
Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
01 May 2023 //
BUSINESSWIRE
